535 related articles for article (PubMed ID: 11581185)
1. Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma.
Scholes AG; Liloglou T; Maloney P; Hagan S; Nunn J; Hiscott P; Damato BE; Grierson I; Field JK
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2472-7. PubMed ID: 11581185
[TBL] [Abstract][Full Text] [Related]
2. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma.
Merbs SL; Sidransky D
Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):779-83. PubMed ID: 10067984
[TBL] [Abstract][Full Text] [Related]
3. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development.
Pollock PM; Welch J; Hayward NK
Cancer Res; 2001 Feb; 61(3):1154-61. PubMed ID: 11221846
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
[TBL] [Abstract][Full Text] [Related]
7. Multiple locations on chromosome 3 are the targets of specific deletions in uveal melanoma.
Cross NA; Ganesh A; Parpia M; Murray AK; Rennie IG; Sisley K
Eye (Lond); 2006 Apr; 20(4):476-81. PubMed ID: 15920570
[TBL] [Abstract][Full Text] [Related]
8. Deletion of chromosomes 9p and 17 associated with abnormal expression of p53, p16/MTS1 and p15/MTS2 gene protein in hepatocellular carcinomas.
Shao J; Li Y; Li H; Wu Q; Hou J; Liew C
Chin Med J (Engl); 2000 Sep; 113(9):817-22. PubMed ID: 11776078
[TBL] [Abstract][Full Text] [Related]
9. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.
Ingvarsson S; Agnarsson BA; Sigbjornsdottir BI; Kononen J; Kallioniemi OP; Barkardottir RB; Kovatich AJ; Schwarting R; Hauck WW; Huebner K; McCue PA
Cancer Res; 1999 Jun; 59(11):2682-9. PubMed ID: 10363992
[TBL] [Abstract][Full Text] [Related]
10. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer.
Fullwood P; Marchini S; Rader JS; Martinez A; Macartney D; Broggini M; Morelli C; Barbanti-Brodano G; Maher ER; Latif F
Cancer Res; 1999 Sep; 59(18):4662-7. PubMed ID: 10493522
[TBL] [Abstract][Full Text] [Related]
11. Lymph node metastasis is associated with allelic loss on chromosome 13q12-13 in esophageal squamous cell carcinoma.
Harada H; Tanaka H; Shimada Y; Shinoda M; Imamura M; Ishizaki K
Cancer Res; 1999 Aug; 59(15):3724-9. PubMed ID: 10446988
[TBL] [Abstract][Full Text] [Related]
12. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma.
Takita J; Hayashi Y; Kohno T; Yamaguchi N; Hanada R; Yamamoto K; Yokota J
Cancer Res; 1997 Mar; 57(5):907-12. PubMed ID: 9041193
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma.
Obermann EC; Diss TC; Hamoudi RA; Munson P; Wilkins BS; Camozzi ML; Isaacson PG; Du MQ; Dogan A
J Pathol; 2004 Feb; 202(2):252-62. PubMed ID: 14743509
[TBL] [Abstract][Full Text] [Related]
14. Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma.
Zhang X; Xu HJ; Murakami Y; Sachse R; Yashima K; Hirohashi S; Hu SX; Benedict WF; Sekiya T
Cancer Res; 1994 Aug; 54(15):4177-82. PubMed ID: 8033150
[TBL] [Abstract][Full Text] [Related]
15. Molecular evidence supporting field effect in urothelial carcinogenesis.
Jones TD; Wang M; Eble JN; MacLennan GT; Lopez-Beltran A; Zhang S; Cocco A; Cheng L
Clin Cancer Res; 2005 Sep; 11(18):6512-9. PubMed ID: 16166427
[TBL] [Abstract][Full Text] [Related]
16. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract][Full Text] [Related]
17. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
18. Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer.
Tseng SL; Yu IC; Yue CT; Chang SF; Chang TM; Wu CW; Shen CY
Genes Chromosomes Cancer; 1997 Dec; 20(4):377-82. PubMed ID: 9408754
[TBL] [Abstract][Full Text] [Related]
19. Genetic alterations of chromosome band 9p21-22 in head and neck cancer are not restricted to p16INK4a.
Waber P; Dlugosz S; Cheng QC; Truelson J; Nisen PD
Oncogene; 1997 Oct; 15(14):1699-704. PubMed ID: 9349503
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer.
Bièche I; Lidereau R
Mol Carcinog; 2000 Nov; 29(3):151-8. PubMed ID: 11108660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]